These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33470246)

  • 1. [Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
    Fazio G; Squizzato A; Mazzetti M; Mannarini A; Fischetti A; Colonna P
    G Ital Cardiol (Rome); 2021 Jan; 22(1):70-79. PubMed ID: 33470246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.
    Colonna P; von Heymann C; Santamaria A; Matsushita Y; Unverdorben M
    Clin Cardiol; 2018 Sep; 41(9):1123-1129. PubMed ID: 30069910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wilkins R; Jin J; Chen C; Colonna P
    Pacing Clin Electrophysiol; 2022 Jan; 45(1):83-91. PubMed ID: 34662445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE.
    Santamaria A; Chen C; Colonna P; von Heymann C; Saxena M; Vanassche T; Jin J; Unverdorben M
    Clin Appl Thromb Hemost; 2023; 29():10760296231200223. PubMed ID: 37697813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
    Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
    JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe].
    Ameri P; Riva L; Toma M; Di Pasquale G; De Caterina R
    G Ital Cardiol (Rome); 2020 Jul; 21(7):546-557. PubMed ID: 32555574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
    Steffel J; Ruff CT; Braunwald E; Hamershock RA; Murphy SA; Nieminen M; Lanz HJ; Mercuri MF; Peterson N; Antman EM; Giugliano RP
    Europace; 2019 Feb; 21(2):306-312. PubMed ID: 30462220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE; Merino JL; Barrios V
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
    Bonaca MP; Antman EM; Cunningham JW; Wiviott SD; Murphy SA; Halperin JL; Weitz JI; Grosso MA; Lanz HJ; Braunwald E; Giugliano RP; Ruff CT
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):695-706. PubMed ID: 34962979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.